Market Place
Sourcing Support
Alto Neuroscience Appoints Andrew Miller to Board
28 May 2026 //
BUSINESSWIRE
Alto Neuroscience CEO Amit Etkin Wins Columbia Research Award
15 May 2026 //
BUSINESSWIRE
Alto Neuroscience Reports Q1 2026 Results and Business Highlights
13 May 2026 //
BUSINESSWIRE
Alto Neuroscience Presents Phase 2a ALTO-207 Data in MDD at SOBP
04 May 2026 //
BUSINESSWIRE
Alto Neuroscience Starts Phase 2b Trial for Resistant Depression
21 Apr 2026 //
BUSINESSWIRE
Alto Halts Work On PDE4 Inhibitor After Ph. 2 Schizophrenia Fail
02 Apr 2026 //
FIERCE BIOTECH
Alto Neuroscience Reports Phase 2 Topline Data for ALTO-101
01 Apr 2026 //
BUSINESSWIRE
Alto Neuroscience Reports Full Year 2025 Financial Results
16 Mar 2026 //
BUSSINESSWIRE
Alto Neuroscience Announces Participation At The Stifel 2026
13 Mar 2026 //
BUSSINESSWIRE
Alto Neuroscience To Participate In Investor Conferences
23 Feb 2026 //
BUSINESSWIRE
Alto Neuroscience Wraps Up Enrollment of ALTO-101 Phase 2 Study
13 Feb 2026 //
BUSINESSWIRE
Alto Neuroscience Highlights Neuroplasticity in Psychiatric Care
03 Feb 2026 //
BUSINESSWIRE
Alto Neuroscience Secures Patent for ALTO-207 in Depression
14 Jan 2026 //
BUSINESSWIRE
Alto Neuroscience Presents New Data at ACNP 2026 Meeting
13 Jan 2026 //
BUSINESSWIRE
Alto Neuroscience: New Inducement Stock Grants Under NYSE Rule
03 Dec 2025 //
BUSINESSWIRE
Alto Neuroscience Reveals Q3 2025 Financials & Business Updates
12 Nov 2025 //
BUSINESSWIRE
Alto Neuroscience To Participate In Upcoming Investor Conferences
28 Oct 2025 //
BUSINESSWIRE
Alto Neuro to Advance ALTO-207 for Treatment-Resistant Depression
20 Oct 2025 //
BUSINESSWIRE
Alto Neuroscience Reveals $50M Private Placement Financing
20 Oct 2025 //
BUSINESSWIRE
Alto Neuro`s ALTO-101 Granted FDA Fast Track Designation
03 Oct 2025 //
BUSINESSWIRE
Alto Neuro EEG Biomarker IDs Cognitive Issues in Schizophrenia
09 Sep 2025 //
BUSINESSWIRE
Alto Neuroscience to Participate in Upcoming Investor Conferences
18 Aug 2025 //
BUSINESSWIRE
Alto Neuroscience Adds Biotech Veteran Raymond Sanchez to Board
13 Aug 2025 //
BUSINESSWIRE
Alto Neuroscience Q2 2025 Financial Results and Highlights
13 Aug 2025 //
BUSINESSWIRE
Alto Neuroscience Highlights PAX-D Study in The Lancet Psychiatry
30 Jun 2025 //
BUSINESSWIRE
Alto’s Phase 2 Depression Trial Misses Primary Efficacy Endpoint
27 Jun 2025 //
FIERCE BIOTECH
Alto Reports Biomarker, Ph 2 Results for ALTO-203
26 Jun 2025 //
BUSINESSWIRE
Alto Neuroscience Acquires Dopamine Agonist for Depression Study
03 Jun 2025 //
BUSINESSWIRE
Alto Neuroscience Data at 2025 ASCP Meeting on ALTO-300 Safety
29 May 2025 //
BUSINESSWIRE
Alto Neuroscience to Participate in Upcoming Investor Conferences
28 May 2025 //
BUSINESSWIRE
Alto Neuroscience Reports Q1 2025 Financial Results & Highlights
14 May 2025 //
BUSINESSWIRE
Alto Neuroscience Presents New Data
28 Apr 2025 //
BUSINESSWIRE
Alto Neuroscience Joins JonesResearch Virtual CNS Day
22 Apr 2025 //
BUSINESSWIRE
Alto Neuroscience Reports Full-Year 2024 Financial Results
20 Mar 2025 //
BUSINESSWIRE
Alto Neuroscience to Participate in Upcoming Investor Conferences
25 Feb 2025 //
BUSINESSWIRE
Alto Neuroscience Gets U.S. Patent For ALTO-300 In MDD Treatment
19 Feb 2025 //
BUSINESSWIRE
Alto Neuroscience Reports Positive Interim Data For ALTO-300 In MDD
12 Feb 2025 //
BUSINESSWIRE
Alto Neuroscience Announces Data at 63rd Annual Meeting
11 Dec 2024 //
BUSINESSWIRE
Alto Neuroscience Reports Q3 2024 Results & Business Highlights
12 Nov 2024 //
BUSINESSWIRE
Alto’s midphase depression trial falls flat
23 Oct 2024 //
FIERCE BIOTECH
Alto Publishes Study on Cognitive Performance and Antidepressants
04 Sep 2024 //
BUSINESSWIRE
Alto Neuroscience to Participate in Upcoming Investor Conferences
03 Sep 2024 //
BUSINESSWIRE
Alto Neuroscience Reports Q2 2024 Results And Business Highlights
13 Aug 2024 //
BUSINESSWIRE
Alto Neuroscience Gets Wellcome Trust Funding For ALTO-100 Development
25 Jul 2024 //
BUSINESSWIRE
Alto Neuroscience Completes Enrollment For ALTO-100 MDD Phase 2b Study
16 Jul 2024 //
BUSINESSWIRE
Amit Etkin Named EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
18 Jun 2024 //
BUSINESSWIRE
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
29 May 2024 //
BUSINESSWIRE
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
21 May 2024 //
BUSINESSWIRE
Alto Neuroscience Reports Q1 2024 Results, Business Highlights
14 May 2024 //
BUSINESSWIRE
Alto Neuroscience Pipeline, Platform Data At Conferences
09 May 2024 //
BUSINESSWIRE
Alto Neuroscience Announces Positive Phase 1 Data for ALTO-101
23 Apr 2024 //
BUSINESSWIRE
Alto Neuro Announces Initiation of Ph 2 Study of ALTO-203 in Patients with MDD
03 Apr 2024 //
BUSINESSWIRE
Alto Neuroscience Reports Full Year 2023 Financial Results
21 Mar 2024 //
BUSINESSWIRE
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
11 Mar 2024 //
BUSINESSWIRE
Alto Neuroscience to Participate in Upcoming Investor Conferences
07 Mar 2024 //
BUSINESSWIRE
Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
27 Feb 2024 //
BUSINESSWIRE
Alto Neuroscience Announces Closing of Upsized Initial Public Offering
06 Feb 2024 //
BUSINESSWIRE
Alto, Fractyl head to public markets with IPOs north of $100M
02 Feb 2024 //
FIERCE BIOTECH
Alto Neuroscience Announces Pricing of Upsized Initial Public Offering
01 Feb 2024 //
BUSINESSWIRE
Alto Neuroscience preps IPO to push CNS therapies through clinic
16 Jan 2024 //
FIERCE BIOTECH
